Session » (0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

Date: Sunday, October 26, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 0613

A Baseline Kidney Biopsy Is Not Always Feasible in Incident Lupus Nephritis: Insights From an Inception Cohort

10:30AM-12:30PM: Abstract Number: 0636

AA Novel Kidney-Specific Biomarker Panel Accurately Differentiates Lupus Nephritis from Diabetic Kidney Disease through Distinct Molecular Pathways Novel Kidney-Specific Biomarker Panel Accurately Differentiates Lupus Nephritis from Diabetic Kidney Disease through Distinct Molecular Pathways

10:30AM-12:30PM: Abstract Number: 0607

Age at Diagnosis of SLE has Increased in a United States Longitudinal Cohort

10:30AM-12:30PM: Abstract Number: 0631

Antibodies to Type I and Type III Interferons at Diagnosis Predispose to Serious Infections on Follow Up in an Inception cohort of SLE (INSPIRE) from India.

10:30AM-12:30PM: Abstract Number: 0604

Assessment of the Metabolic Score for Insulin Resistance (METS-IR) and Its Associated Factors in Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0634

Association of Lifestyle and Integrative Health Practices with Health-Related Quality of Life in Women with Systemic Lupus Erythematosus and Connective Tissue Disease

10:30AM-12:30PM: Abstract Number: 0602

Association of Systemic Lupus Erythematosus with Healthcare Resource Utilization and Healthcare Expenditures: Analysis of Nationally Representative Data, 2017-2022

10:30AM-12:30PM: Abstract Number: 0617

Autoantibodies to Extracellular Antigens in Lupus Patients Serum Versus Controls; Predominance of Autoantibodies to Type I Interferons in Lupus Sera

10:30AM-12:30PM: Abstract Number: 0629

Characterizing Arthritis Subtypes in SLE: Prevalence, Clinical Features, and the Role of Type I Interferon Signatures

10:30AM-12:30PM: Abstract Number: 0623

Cluster Analysis of Socioeconomic and Environmental Determinants Modifying Activity, Chronicity and Clinical Manifestations of Systemic Lupus Erythematosus in the GLADEL 2.0 Cohort

10:30AM-12:30PM: Abstract Number: 0632

Comparative Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Patients with Systemic Lupus Erythematosus and Diabetes: A Propensity-Matched Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 0635

Comparison of the SARC-F with Objective Measures of Sarcopenia in Women with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0630

Development, Validation and Performance of a Patient Knowledge Assessment Tool for Assessing the Immediate and Short-term Impact of an Information Course in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0633

Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis (AAV) and Systemic Lupus Erythematosus (SLE): A Comparative Analysis

10:30AM-12:30PM: Abstract Number: 0637

DNA Methylation Patterns Differ Between Genetically Similar Systemic Lupus Erythematosus (SLE) Patients From Peru and the U.S.

10:30AM-12:30PM: Abstract Number: 0625

DNA methylation patterns in systemic lupus erythematosus associated with nephritis status

10:30AM-12:30PM: Abstract Number: 0596

Effect of Gender and Follow-up Time in Damage Accrual: Data from a Latin America Lupus Cohort

10:30AM-12:30PM: Abstract Number: 0599

Efficacy of Statin Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0614

Evaluating Cardiovascular Risk in Systemic Lupus Erythematosus: Comparing Novel Risk Scores with Carotid Ultrasound

10:30AM-12:30PM: Abstract Number: 0626

Evaluation of Novel Anti-ATP1A1 Autoantibodies by ELISA to Predict Cardiac Neonatal Lupus (Cardiac-NL)

10:30AM-12:30PM: Abstract Number: 0593

Genetic Risk Profiles Predict Clinical Heterogeneity in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0640

Impact of Clinically Important Improvements in Patient-Reported Outcomes on Disease Activity in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib or Placebo: Results From the Phase 2 SLEek Study

10:30AM-12:30PM: Abstract Number: 0606

Increased Recombinant Zoster Vaccination in SLE following Public Reimbursement: Data from Two Prospective SLE Cohorts

10:30AM-12:30PM: Abstract Number: 0619

Interim Analysis of the Impact of a Recombinant Herpes Zoster Vaccine on Systemic Lupus Erythematosus: A Randomized Controlled Study on Immunogenicity, Safety and Immunosuppressor Effects

10:30AM-12:30PM: Abstract Number: 0612

Is Antimalarial Use Associated with a Reduced Risk of Lupus Nephritis in Patients with SLE? Results from an Inception Cohort-Based Study

10:30AM-12:30PM: Abstract Number: 0639

Kidney Transplantation In Lupus Nephritis. Multicenter Study Of 103 Patients

10:30AM-12:30PM: Abstract Number: 0597

Low 25-hydroxyvitamin D Levels are Associated with Higher Mortality and More Cardiovascular Events in Systemic Lupus Erythematosus

10:30AM-12:30PM: Abstract Number: 0627

Marked Decline in SLE Mortality Despite Rising Mortality in the General Population During the COVID-19 Pandemic

10:30AM-12:30PM: Abstract Number: 0616

Neurofilament Light Chain Serum Levels is Associated with Neuropsychiatric Manifestations and Cognitive Dysfunction in Systemic Lupus Erythematosus Patients: A Longitudinal Study

10:30AM-12:30PM: Abstract Number: 0609

Neutropenia in SLE: a Retrospective Cohort Study of Etiologies, Severity, Management, and Infection Outcomes

10:30AM-12:30PM: Abstract Number: 0594

Patients with SLE Have an Increased Bisphenol A Methylation Score Linked to SLE Risk Genes and Immune Response Pathways

10:30AM-12:30PM: Abstract Number: 0624

Polygenic risk of lupus is differentially associated with individual EHR-derived classification criteria

10:30AM-12:30PM: Abstract Number: 0601

Precipitants and Long-Term Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort Study and Systematic Review

10:30AM-12:30PM: Abstract Number: 0638

Prevalence of lupus nephritis, end stage kidney disease, avascular necrosis, and mortality in systemic lupus erythematosus in the recent era

10:30AM-12:30PM: Abstract Number: 0621

Risk Factors for Pulmonary Manifestations in GLADEL 2.0, a Systemic Lupus Erythematosus Latin American Cohort

10:30AM-12:30PM: Abstract Number: 0622

Shrinking Lung Syndrome in Systemic Lupus Erythematosus: A Pooled Database Analysis of Clinical, Immunological and Therapeutic Factors Impacting Outcomes

10:30AM-12:30PM: Abstract Number: 0608

Strong Correlation Between SLEDAI and SLE-DAS in the Spanish Population: Assessment of Discordant Patients

10:30AM-12:30PM: Abstract Number: 0598

Study of Long Term HCQ Safety on Cardiac Muscle Function in Patients with SLE and other Rheumatic Diseases

10:30AM-12:30PM: Abstract Number: 0595

Sustained Remission In SLE Is Infrequent On Standard Of Care: A Decade Of Insights From The Asia Pacific Lupus Collaboration

10:30AM-12:30PM: Abstract Number: 0615

Systemic Lupus Erythematosus Flares in Patients with End-Stage Kidney Disease on Renal Replacement Therapy or after Transplant

10:30AM-12:30PM: Abstract Number: 0610

The Role of Active Nephritis, Compared to Active Non-Renal SLE, in Pregnancy Outcomes

10:30AM-12:30PM: Abstract Number: 0605

The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Worsening Self-Efficacy in the Patients from the Almenara Lupus Cohort

10:30AM-12:30PM: Abstract Number: 0620

The usefulness of neutrophil-to-lymphocyte ratio as a biomarker to predict lupus flares in patients under remission

10:30AM-12:30PM: Abstract Number: 0618

Therapeutic landscape of systemic lupus erythematosus pure membranous nephropathy: a nationwide population-based study

10:30AM-12:30PM: Abstract Number: 0600

Toward a Consensus-Based Definition of Difficult-to-Treat Systemic Lupus Erythematosus: A Multinational Survey of Clinicians from the MENA Region

10:30AM-12:30PM: Abstract Number: 0603

Transverse Myelitis in Systemic Lupus Erythematosus: Disease Manifestations and Clinical Outcomes from Multi-Center Data

10:30AM-12:30PM: Abstract Number: 0611

Venous Thromboembolism in Patients with Lupus Nephritis: Frequency and Risk Factors – A Cohort Study

10:30AM-12:30PM: Abstract Number: 0628

Α user-friendly machine-learning tool for early damage prediction in patients with Systemic Lupus Erythematosus

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].